Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.

L.H. van der Helm; C. Alhan; P.W. Wijermans; M. van Marwijk-Kooy; R. Schaafsma; B.J. Biemond; A. Beeker; M. Hoogendoorn; B.P. van Rees; O. de Weerdt; J. Wegman; W.J. Libourel; S.A. Luykx-de Bakker; M.C. Minnema; R.E. Brouwer; F. Croon-de Boer; M. Eefting; K-S.G. Jie; A.A. van de Loosdrecht; J. Koedam; N.G.J.M. Veeger; E. Vellenga; G. Huls

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.

Translated title of the contribution: Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.

L.H. van der Helm
, C. Alhan
, P.W. Wijermans
, M. van Marwijk-Kooy
, R. Schaafsma
, B.J. Biemond
, A. Beeker
, M. Hoogendoorn
, B.P. van Rees
, O. de Weerdt
, J. Wegman
, W.J. Libourel
, S.A. Luykx-de Bakker
, M.C. Minnema
, R.E. Brouwer
, F. Croon-de Boer
, M. Eefting
, K-S.G. Jie
, A.A. van de Loosdrecht
, J. Koedam

N.G.J.M. Veeger, E. Vellenga, G. Huls

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
Original language	Undefined/Unknown
Pages (from-to)	599-606
Number of pages	8
Journal	British Journal of Haematology
Volume	155
Issue number	5
Publication status	Published - 2011

Cite this

van der Helm, L. H., Alhan, C., Wijermans, P. W., van Marwijk-Kooy, M., Schaafsma, R., Biemond, B. J., Beeker, A., Hoogendoorn, M., van Rees, B. P., de Weerdt, O., Wegman, J., Libourel, W. J., Luykx-de Bakker, S. A., Minnema, M. C., Brouwer, R. E., Croon-de Boer, F., Eefting, M., Jie, K.-SG., van de Loosdrecht, A. A., ... Huls, G. (2011). Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. British Journal of Haematology, 155(5), 599-606.

van der Helm, L.H. ; Alhan, C. ; Wijermans, P.W. et al. / Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. In: British Journal of Haematology. 2011 ; Vol. 155, No. 5. pp. 599-606.

@article{30ec36b9a70b48b68200cfa530e9b2f5,

title = "Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.",

author = "\{van der Helm\}, L.H. and C. Alhan and P.W. Wijermans and \{van Marwijk-Kooy\}, M. and R. Schaafsma and B.J. Biemond and A. Beeker and M. Hoogendoorn and \{van Rees\}, B.P. and \{de Weerdt\}, O. and J. Wegman and W.J. Libourel and \{Luykx-de Bakker\}, S.A. and M.C. Minnema and R.E. Brouwer and \{Croon-de Boer\}, F. and M. Eefting and K-S.G. Jie and \{van de Loosdrecht\}, A.A. and J. Koedam and N.G.J.M. Veeger and E. Vellenga and G. Huls",

year = "2011",

language = "Undefined/Unknown",

volume = "155",

pages = "599--606",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley \& Sons Inc.",

number = "5",

}

van der Helm, LH, Alhan, C, Wijermans, PW, van Marwijk-Kooy, M, Schaafsma, R, Biemond, BJ, Beeker, A, Hoogendoorn, M, van Rees, BP, de Weerdt, O, Wegman, J, Libourel, WJ, Luykx-de Bakker, SA, Minnema, MC, Brouwer, RE, Croon-de Boer, F, Eefting, M, Jie, K-SG, van de Loosdrecht, AA, Koedam, J, Veeger, NGJM, Vellenga, E & Huls, G 2011, 'Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.', British Journal of Haematology, vol. 155, no. 5, pp. 599-606.

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. / van der Helm, L.H.; Alhan, C.; Wijermans, P.W. et al.
In: British Journal of Haematology, Vol. 155, No. 5, 2011, p. 599-606.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.

AU - van der Helm, L.H.

AU - Alhan, C.

AU - Wijermans, P.W.

AU - van Marwijk-Kooy, M.

AU - Schaafsma, R.

AU - Biemond, B.J.

AU - Beeker, A.

AU - Hoogendoorn, M.

AU - van Rees, B.P.

AU - de Weerdt, O.

AU - Wegman, J.

AU - Libourel, W.J.

AU - Luykx-de Bakker, S.A.

AU - Minnema, M.C.

AU - Brouwer, R.E.

AU - Croon-de Boer, F.

AU - Eefting, M.

AU - Jie, K-S.G.

AU - van de Loosdrecht, A.A.

AU - Koedam, J.

AU - Veeger, N.G.J.M.

AU - Vellenga, E.

AU - Huls, G.

PY - 2011

Y1 - 2011

M3 - Article

SN - 0007-1048

VL - 155

SP - 599

EP - 606

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 5

ER -

van der Helm LH, Alhan C, Wijermans PW, van Marwijk-Kooy M, Schaafsma R, Biemond BJ et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. British Journal of Haematology. 2011;155(5):599-606.